Zymeworks is a clinical-stage biotechnology company unlocking new possibilities in cancer and autoimmune disease treatment. Our mission is to make a meaningful difference in the lives of patients by advancing a growing pipeline of next-generation antibody therapeutics, including T cell engagers and antibody-drug conjugates (ADCs).
Our lead asset, zanidatamab—a HER2-targeted bispecific antibody— is partnered with Jazz Pharmaceuticals and BeOne Medicines and is approved in the U.S. and China for previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. We’re also rapidly advancing a robust pipeline of wholly-owned ADC and multispecific programs designed to target areas of significant unmet medical need.
With integrated R&D capabilities and a proven track record of scientific innovation and collaboration, we’re building strategic partnerships and a culture where passionate people can make an impact.
Join us as we engineer what’s next in biotherapeutics.
Company Details
- Employees
- 303
- Founded
- -
- Address
- 114 E 4th Avenue, Suite 800,canada
- Phone
- (604)678-1388
- in****@****rks.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- zymeworks.com
- Keywords
- antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, Biliary Tract Cancer.
- HQ
- Vancouver, BC
Zymeworks Inc. Questions
Zymeworks Inc.'s helpline number is (604)678-1388
Zymeworks Inc.'s website is zymeworks.com
Zymeworks Inc.'s LinkedIn profile is https://ca.linkedin.com/company/zymeworks
Zymeworks Inc. has
303 employees.
View email and phone details for 303
employees at Zymeworks Inc..
Zymeworks Inc.'s industry is
Biotechnology Research
Zymeworks Inc.'s top competitors are
Life Sciences Bc,
Abcellera,
Notch Therapeutics,
Acuitas Therapeutics,
Nanovation Therapeutics™,
Aspect Biosystems,
Stemcell Technologies,
Abdera Therapeutics,
Xenon Pharmaceuticals Inc.,
Admare Bioinnovations.
Zymeworks Inc.'s support email address is info@zymeworks.com
Zymeworks Inc.'s categories are Biotechnology Research
Zymeworks Inc.'s founding year is 2003
